Olivier Bohuon - Smith Nephew Insider

Smith Nephew plc -- USA Stock  

USD 18.30  0.000001  0.00%

CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee

Mr. Olivier Bohuon is Chief Executive Officer, Executive Director of Smith and Nephew PLC. Olivier holds a doctorate in Pharmacy from the University of Paris and an MBA from HEC, Paris. He started his career in Morocco with Roussel Uclaf S.A. and then, with the same company, held a number of positions in the Middle East with increasing levels of responsibility. He joined Abbott in Chicago as head of their antiinfective franchise with Abbott International before becoming Pharmaceutical General Manager in Spain. He subsequently joined GlaxoSmithKline plc, rising to Senior Vice President Director for European Commercial Operations. He then rejoined Abbott as President for Europe, became President of Abbott International, and then President of their Pharmaceutical Division. He joined Smith Nephew from Pierre Fabre, where he was Chief Executive. Olivier has extensive international healthcare leadership experience within a number of significant pharmaceutical and healthcare companies. His global experience provides the skillset required to innovate a FTSE 100 company with a deep heritage and provide inspiring leadership. He is a NED of Virbac Group and Shire plc, where he is also a member of the Remuneration Committee and the Nomination Governance Committee and will be appointed Senior Independent Director on 25 April 2018.
Age: 58  Chairman Since 2011  MBA    
44 20 7401 7646  http://www.smith-nephew.com

Management Efficiency

The company has return on total asset (ROA) of 7.27 % which means that it generated profit of $7.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 17.83 % meaning that it generated $17.83 on every $100 dollars invested by stockholders.
The company has accumulated 1.45 B in total debt with debt to equity ratio (D/E) of 31.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Smith Nephew plc has Current Ratio of 1.99 which is within standard range for the sector.

Similar Executives

Found 3 records


Paul ManducaPrudential plc
Barry StowePrudential plc
Jeffery BoydBooking Holdings Inc

Entity Summary

Smith Nephew plc designs, develops, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom. Smith Nephew is traded on OTC Market in USA.Smith Nephew plc (SNNUF) is traded on OTC Market in USA. It is located in 15 Adam Street and employs 15,933 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Smith Nephew plc to your portfolio

Top Management

Smith Nephew plc Leadership Team
Michael Friedman, Director, Ph.D
Diogo MoreiraRato, President
Erik Engstrom, Director, MBA
Matthew Stober, President
Marc Owen, Director, MBA
Rodrigo Bianchi, President
Brian Larcombe, Director
Elga Lohler, Executive
Gunthorp Oie, Executive
Roland Diggelmann, Director
Helen Maye, Executive
Vinita Bali, Director, MBA
Olivier Bohuon, Chairman, MBA
Graham Baker, Director
Roberto Quarta, Chairman
Cyrille Petit, Executive
Julie Brown, Director, MBA
Glenn Warner, President
Robin Freestone, Director
Virginia Bottomley, Director
Angie Risley, Director
Vasant Padmanabhan, President, MBA
Michael Frazzette, President
Joseph Papa, Director, MBA
Ingeborg Oie, VP
Susan Swabey, Executive
Gordon Howe, President
John Campo, Executive
Brad Cannon, President
Ian Barlow, Director
Catheryn ORourke, Executive

Stock Performance

Smith Nephew Performance Indicators